Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: On May 9 2019, a poster attributed to Delta Airlines apparently urging workers to forgo union dues in favor of purchasing video gaming consoles circulated on Facebook and Twitter:lol fuck off @Delta pic.twitter.com/fMNOeW9uFG Eoin Higgins (@EoinHiggins_) May 9, 2019Above a rendering of a video game controller, blue and red text urged Delta employees to purchase expensive consoles instead of paying union dues:UNION DUES COST AROUND $700 A YEARA NEW VIDEO GAME SYSTEM WITH THE LATEST HITS SOUNDS LIKE FUN. PUT YOUR MONEY TOWARDS THAT INSTEAD OF PAYING DUES TO THE UNION.The image also featured Delta's logo and a website: DontRiskItDontSignIt.com. Eoin Higgins' tweet above was shared more than 50,000 times in under six hours:Yikes, @Delta. Call us when Xbox makes a model that can raise wages, guarantee paid leave, and make jobs safer and more secure. Until then, we're sticking with the #union. #1u https://t.co/8Bb8phfzeK Transp. Trades Dept. (@TTDAFLCIO) May 9, 2019Union contract: ✅ Can afford a new video game system ✅ Guard against bad bosses ✅ If I get laid off my boss has to negotiate the terms with my union ✅ Free access to lawyers ✅ More benefitsVideo game system: you have $700 lessDelta help me I'm not sure what to decide Brett Banditelli (@banditelli) May 9, 2019Reminder that companies only start printing anti-union myths and propaganda once they start seeing worker power in action and realize what they are up against.Keep it up Delta employees! ✊🏿✊🏼✊🏾 https://t.co/UV8wlJ6tKg Game Workers Unite ✊🏿✊🏽✊🏾 (@GameWorkers) May 9, 2019Wow. Delta would give you plenty of time to play video games when they fire you for no good reason because you're an At Will employee. But a union contract protects your paycheck from arbitrary terminations. @AFLCIO @EoinHiggins_ pic.twitter.com/bM9cTtWn0o RWDSU (@RWDSU) May 9, 2019The image shared by Higgins was also shared to Reddit's r/WTF and r/ChapoTrapHouse:Gamers please don't rise up. from ChapoTrapHouseIn response to questions about the origin of the image, Higgins said that he would explain further in an upcoming article:I'll have answers to that and more in a piece Eoin Higgins (@EoinHiggins_) May 9, 2019Delta's anti-union site DontRiskItDontSignIt.comfeatured a "printables" section, but the viral "video games" poster had either been removed, or it had never appeared on the site to begin with. However, many of the available images closely resembled the poster:One of the "printables" available as of May 9 2019 (archived here) featured a structure similar to the circulating image:However, we were unable to locate any images of the same poster uploaded to the internet prior to Higgins' tweet. On the day the tweet began circulating, IAM issued a statement about attacks from Delta on thewebsiteIAMDelta.net and on Twitter:Our statement on @Delta's attack on their own employees. #DoBetterDelta pic.twitter.com/2Kby5wTkbu Machinists Union (@MachinistsUnion) May 9, 2019We contacted Delta and the International Association of Machinists (IAM, the target of Delta's union-busting efforts) to ask about the origin and authenticity of the "video games" poster. We have received no response from the airline, but the union confirmed their existence on Twitter:In employee break rooms. Machinists Union (@MachinistsUnion) May 9, 2019There was more than one poster in the same vein, all of which shared the aesthetic of the website:Video games, baseball, and football? Really @Delta? Our workers want a voice on the job. #GameOverDelta #1u pic.twitter.com/AdSgxSxVHh AFL-CIO (@AFLCIO) May 10, 2019According to investigative journalism site Sludge, the site and posters are the work of a public relations firm that is notorious for its aggressive campaigns:FTI employees don't just create websites and messaging. They also work as undercover agents for some of their clients.Earlier this year, FTI employees posed as journalists for Western Wireanother website that shares a server with Delta's anti-union siteand attempted to question attorneys working with environmental nonprofit EarthRights International about its lawsuit against ExxonMobil. Legal ethics prohibit attorneys from speaking with representatives for opposing parties without their attorneys being present, so the attempt by FTI to question the EarthRights International attorneys under the guise of journalism can easily be seen as an attempt to circumvent legal ethics to gather intel for their client, ExxonMobil.We asked Delta for comment, but have not yet heard back.
[EX A]: Delta Airlines created a union-busting poster urging workers to buy video gaming consoles with would-be union dues.

[EX Q]: Unlike the all-out defense that Buxton normally puts on display, the Twins were more than willing to play it safe with this injury. Buxton was placed on the seven-day injured list for players with concussion-like symptoms, just as first baseman C.J. Cron and left fielder Eddie Rosario returned from their injuries. The Twins also designated right-handed reliever Mike Morin for release or assignment Tuesday before their series opener against the New York Mets. "We're not going to mess around, really, in any way," manager Rocco Baldelli said. "This is serious stuff. The health of Buck is obviously the most important thing. I think it's something that is already resolving itself in some ways, but something where I think this is the right move." Buxton was hurt Saturday during his head-first, diving catch of a sinking line drive during a critical win at main division competitor Cleveland, forcing him out of the game in the eighth inning. Buxton, who was sidelined for 13 games last month with a bruised right wrist, has had his promising career so far stunted by a variety of injuries, in part due to the speedster's fearless style in the outfield and on the bases. Buxton was announced Tuesday as the team's annual winner of the Major League Baseball Players Alumni Association's Heart and Hustle Award. "He hit the ground pretty hard, and this isn't any sort of light injury," Baldelli said. "He didn't graze anything. He made a great play and hit the ground, and he gives his body up for this team every single night that he takes the field." The Twins, who took a six-game lead in the AL Central over the Indians into Tuesday night, have managed to maintain the highest-scoring offense in the majors despite putting 10 different position players on the injured list over various points of this season. Rosario was out for 13 games with a sprained left ankle. "It's been a tough couple of weeks when it comes to injuries and things like that, but I'm back today and I know what Buxton is going through is nothing bad and he'll be back soon as well," said Rosario, who's second on the team with 20 homers and still leads the Twins with 60 RBIs. Because of the All-Star break, Cron only missed five games with right thumb inflammation, a condition that has bothered him for most of the season. "I'm just going to try to tape it up, I guess. Try to pretend as if nothing's wrong and try to just keep going," Cron said. "That's really all you can do." Morin had a 3.18 ERA in 23 appearances after being invited to spring training on a minor league contract. His somewhat surprising removal from the roster could be the precursor to the addition of a reliever or two on the trade market over the next two weeks. "When you make decisions like this, you can look back on them, and you're not really sure because things are not obvious sometimes, but unfortunately we landed on the thought of designating Mike," Baldelli said. "I have no doubt he's going to land on his feet." ___ More AP baseball coverage: https://apnews.com/MLB and https://twitter.com/AP_Sports
[EX A]: As Cron, Rosario return, Twins put Buxton on concussion list.

[EX Q]: "It's time to go back on offense," Lechleiter said in a recent interview. New treatments for diabetes and cancer now awaiting approval and increased sales of animal-health products and drugs in China and Japan are some of the aggressive moves he has in mind. He is also counting on a robust success rate among three dozen other experimental drugs now in mid- and late-stage trials, including a cancer drug called ramucirumab. "We're on the cusp of launching products in cancer and diabetes, two therapeutic areas where we're well established and where we have built out the infrastructure we need," Lechleiter said. "And we believe that's going to be the beginning of our return to growth." Skeptical investors only now appear to be catching on to Lilly's potential upside. After rising only 3 percent in 2013, badly underperforming a 27 percent average advance for other large drugmakers, the stock is up 6 percent this month. "Instead of having to play defense and manage through this difficult patent cliff, the company will be able to use additional cash flow to invest in its pipeline, to partner with others or make bolt-on acquisitions," said Atlantic Equities analyst Richard Purkiss. "The outlook is much brighter, and they'll try to get that message across in coming months." Lilly, which reports quarterly and 2013 results on Thursday, has forecast earnings of $2.77 to $2.85 per share this year, the final and worst year of its patent cliff. That's 41 percent less than 2010. Lilly last year sought U.S. approvals for four drugs, three of which Lechleiter said could be approved in 2014: ramucirumab for stomach cancer, and dulaglutide and empagliflozin for type 2 diabetes - the most common form of diabetes, which is closely linked to obesity. Analysts have forecast annual sales of more than $650 million for ramucirumab, saying sales could be far higher if the drug also wins approval for cancers of the colon, lung or liver. But they caution that the diabetes drugs may have a hard time competing against existing options. Lechleiter said Lilly plans to seek approval of necitumumab for squamous-cell lung cancer this year. The medicine, like ramucirumab, was acquired by Lilly through its $6.5 billion purchase of ImClone Systems in 2008. If approved, necitumumab could capture eventual annual sales of more than $1 billion, analysts say. Such sales could make a big difference for Lilly, whose annual revenue of $20 billion is far lower than Big Pharma rivals like Pfizer Inc and Merck & Co. In the meantime, Lilly is testing nearly 40 medicines in mid- and late stage studies, compared with only 7 in those stages of development a decade ago. They include new treatments for cholesterol, psoriasis, lupus, rheumatoid arthritis and Alzheimer's disease. Animal health unit Elanco, with annual sales of about $2 billion, is thriving as Lilly introduces new products and has expanded the business in China and other fast-growing markets. Many analysts are wary, however, of the company's ability to win approvals of prescription drugs because it has not launched any major products in recent years and has suffered setbacks in clinical trials, including ramucirumab's failure to delay progression of breast cancer. Of 20 analysts tracked by Thomson Reuters, 12 have hold or sell ratings on Lilly, versus 8 with buy ratings. Lilly shares trade at 19 times expected 2014 per-share earnings, compared to a price-to-earnings ratio of 14.6 for other large drugmakers. That could be more a reflection of the company's poor earnings this year than excitement about the stock. "We believe that overall the pipeline will disappoint investors," said Alex Arfaei of BMO Capital Markets in a research note, citing low sales expectations for ramucirumab and the new diabetes drugs. When Lilly's Zyprexa was confronted with cheaper generic treatments for schizophrenia in October 2011, it faced one of the industry's steepest patent cliffs ever, quickly losing 80 percent of its onetime $5 billion in annual sales. Similarly precipitous declines are expected for Cymbalta, Lilly's $5 billion-a-year antidepressant, which lost U.S. patent protection last month, and for blockbuster osteoporosis treatment Evista, which goes generic in March. Many other large drugmakers, when faced with patent expirations and earnings declines of lesser scope, have resorted to megamergers to cushion the blow from generics and prop up earnings with cost savings. Huge layoffs, sapped morale and poor track records in introducing new drugs are more common results. Pfizer Inc stands out, having snapped up U.S. rivals Warner-Lambert, Pharmacia and Wyeth since 2000. Lechleiter, who began his career at Lilly in 1979 as a senior organic chemist, has steadfastly spurned any suggestion of a big merger: "It's never entered our minds, and we remain adamantly opposed." John Boris, an analyst for Suntrust Robinson Humphrey, said he expects Lilly earnings to grow an average of 10 percent a year between 2015 and 2020, which would make it second to Bristol-Myers Squibb Co in profit growth over that period. Atlantic Equities' Purkiss said he anticipates Lilly will deliver industry-topping earnings growth in the "mid-teens" percentage range in 2015, 2016 and 2017. "The sentiment has been very negative on Lilly, but it looks like it will go from one of the most growth-starved to the fastest growing of the major U.S. drugmakers and the European players," Purkiss said. By avoiding a disruptive megamerger, Lilly has allowed itself to press ahead with ambitious research, said Barclays analyst Tony Butler. He said to date the company has met long-term sales and earnings forecasts it provided in 2009 - before patents went over the cliff - while maintaining its generous dividend, with a current yield of 3.6 percent. "At the time, the market was incredibly skeptical about Lilly's ability to fund its dividend and to have enough remaining cash flow to fund its business," said Butler. "Lilly proved everybody wrong." (This story has been refiled to change second subhead)
[EX A]:
Lilly CEO: 'It's time to go back on offense'.